

## **Board Member Torsten Goesch Has Passed Away Suddenly**

**STOCKHOLM, SVERIGE - 5 september 2024: Modus Therapeutics Holding AB ("Modus Therapeutics") announces today the sudden passing of board member Torsten Goesch.**

**Modus Therapeutics CEO John Öhd commented:** " *It is with great sadness that we at Modus Therapeutics announce the sudden passing of our board member Torsten Goesch. Torsten was a valued and respected member of our board, and he made significant contributions to the company's development during his time with us. He will be greatly missed. Our thoughts are now with his family and loved ones during this difficult time.*"

Modus Therapeutics' nomination committee has initiated the process of appointing a successor for Torsten Goesch, and further information will be communicated shortly.

**For more information on Modus Therapeutics, please contact:**

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: [john.ohd@modustx.com](mailto:john.ohd@modustx.com)

**Certified Adviser**

Svensk Kapitalmarknadsgranskning AB

Website: [www.skmg.se](http://www.skmg.se)

**About Modus Therapeutics and sevuparin**

Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus' ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at [www.modustx.com](http://www.modustx.com).

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

**Attachments**

**Board Member Torsten Goesch Has Passed Away Suddenly**